Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy for borderline resectable and resectable pancreatic cancer (PREOPANC-2): A multicenter randomized controlled trial

被引：24

作者：

Koerkamp, B. Groot ^{[1
]}

Janssen, Q. P. ^{[1
]}

van Dam, J. L. ^{[1
]}

Bonsing, B. A. ^{[2
]}

Bos, H. ^{[3
]}

Bosscha, K. P. ^{[4
]}

Haberkorn, B. C. M. ^{[5
]}

de Hingh, I. H. J. T. ^{[6
]}

Karsten, T. M. ^{[7
]}

Van der Kolk, M. B. ^{[8
]}

Liem, M. S. L. ^{[9
]}

Loosveld, O. J. L. ^{[10
]}

Patijn, G. A. ^{[11
]}

van Santvoort, H. C. M. ^{[12
]}

de Vos-Geelen, J. ^{[13
]}

van der Holt, B. ^{[14
]}

Homs, M. Y. V. ^{[15
]}

van Tienhoven, G. ^{[16
]}

Besselink, M. G. ^{[17
]}

Wilmink, H. W. ^{[18
]}

机构：

[1] Erasmus MC Canc Inst, Surg, Rotterdam, Netherlands

[2] LUMC Leiden Univ Med Ctr, Surg, Leiden, Netherlands

[3] Ziekenhuis Tjongerschans, Internal Med, Heerenveen, Netherlands

[4] Jeroen Bosch Hosp, Surg, Shertogenbosch, Netherlands

[5] Maasstad Ziekenhuis, Internal Med, Rotterdam, Netherlands

[6] Catharina Hosp, Surg, Eindhoven, Netherlands

[7] OLVG Hosp, Surg, Amsterdam, Netherlands

[8] Radboud Univ Nijmegen, Surg, Med Ctr, Nijmegen, Netherlands

[9] Med Spectrum Twente, Surg, Enschede, Netherlands

[10] Amphia Ziekenhuis Locat Molengracht, Dept Med Oncol, Breda, Netherlands

[11] Isala Hosp, Surg, Zwolle, Netherlands

[12] UMC Univ Med Ctr Utrecht, Surg, Utrecht, Netherlands

[13] Maastricht Univ Med Ctr MUMC, Dept Med Oncol, Maastricht, Netherlands

[14] Erasmus MC Canc Inst, Hematol, Rotterdam, Netherlands

[15] Erasmus MC Canc Inst, Med Oncol, Rotterdam, Netherlands

[16] Univ Amsterdam, Radiat Oncol, Amsterdam UMC, Amsterdam, Netherlands

[17] Univ Amsterdam, Surg, Amsterdam UMC, Amsterdam, Netherlands

[18] Univ Amsterdam, Med Oncol, Amsterdam UMC, Amsterdam, Netherlands

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.10.084

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA83

引用

页码：S1323 / S1323

页数：1

共 50 条

[31] Randomized multicenter phase II/III study with adjuvant gemcitabine versus neoadjuvant/adjuvant FOLFIRINOX in resectable pancreatic cancer: The NEPAFOX trial.
Al-Batran, Salah-Eddin
Reichart, Alexander
Bankstahl, Ulli Simone
Pauligk, Claudia
Kraus, Thomas Werner
Bechstein, Wolf Otto
Trojan, Jorg
Behrend, Matthias
Potenberg, Jochem
Homann, Nils
Venerito, Marino
Bohle, Wolfram
Varvenne, Michael
Bolling, Claus
Behringer, Dirk M.
Kratz-Alber, Karsten
Siegler, Gabriele Margareta
Hozaeel, Wael
Goetze, Thorsten Oliver
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[32] Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial
Versteijne, Eva
Suker, Mustafa
Groothuis, Karin
Akkermans-Vogelaar, Janine M.
Besselink, Marc G.
Bonsing, Bert A.
Buijsen, Jeroen
Busch, Olivier R.
Creemers, Geert-Jan M.
van Dam, Ronald M.
Eskens, Ferry A. L. M.
Festen, Sebastiaan
de Groot, Jan Willem B.
Koerkamp, Bas Groot
de Hingh, Ignace H.
Homs, Marjolein Y., V
van Hooft, Jeanin E.
Kerver, Emile D.
Luelmo, Saskia A. C.
Neelis, Karen J.
Nuyttens, Joost
Paardekooper, Gabriel M. R. M.
Patijn, Gijs A.
van der Sangen, Maurice J. C.
de Vos-Geelen, Judith
Wilmink, Johanna W.
Zwinderman, Aeilko H.
Punt, Cornelis J.
van Eijck, Casper H.
van Tienhoven, Geertjan
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (16) : 1763 - +
[33] Survival benefit of neoadjuvant FOLFIRINOX for patients with borderline resectable pancreatic cancer
Waugh, Evelyn
Glinka, Juan
Breadner, Daniel
Liu, Rachel
Tang, Ephraim
Allen, Laura
Welch, Stephen
Leslie, Ken
Skaro, Anton
ANNALS OF HEPATO-BILIARY-PANCREATIC SURGERY, 2024, 28 (02) : 229 - 237
[34] FOLFIRINOX versus Gemcitabine/nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Adenocarcinoma: A Propensity Matched Analysis
Dhir, M.
Zenati, M. S.
Hamad, A.
Singhi, A. D.
Bahary, N.
Hogg, M.
Zeh, H.
Zureikat, A.
ANNALS OF SURGICAL ONCOLOGY, 2018, 25 : S8 - S8
[35] Preoperative Gemcitabine-Based Chemoradiation Therapy for Resectable and Borderline Resectable Pancreatic Cancer
Takahashi, Hidenori
Ohigashi, Hiroaki
Gotoh, Kunihito
Marubashi, Shigeru
Yamada, Terumasa
Murata, Masayuki
Ioka, Tatsuya
Uehara, Hiroyuki
Yano, Masahiko
Ishikawa, Osamu
ANNALS OF SURGERY, 2013, 258 (06) : 1040 - 1050
[36] Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX
Choi, Yoo Jin
Byun, Yoonhyeong
Kang, Jae Seung
Kim, Hyeong Seok
Han, Youngmin
Kim, Hongbeom
Kwon, Wooil
Oh, Do-Youn
Paik, Woo Hyun
Lee, Sang Hyub
Ryu, Ji Kon
Kim, Yong-Tae
Lee, Kyungbun
Kim, Haeryoung
Chie, Eui Kyu
Jang, Jin-Young
GUT AND LIVER, 2021, 15 (03) : 466 - 475
[37] Neoadjuvant Chemoradiotherapy improves oncological results in resectable and borderline resectable Pancreatic Carcinomas, but not Overall Survival in resectable ones Results of the Dutch PREOPANC Study
Hermann, Robert Michael
Christiansen, Hans
STRAHLENTHERAPIE UND ONKOLOGIE, 2021, 197 (01) : 85 - 88
[38] Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial
Eva Versteijne
Casper H. J. van Eijck
Cornelis J. A. Punt
Mustafa Suker
Aeilko H. Zwinderman
Miriam A. C. Dohmen
Karin B. C. Groothuis
Oliver R. C. Busch
Marc G. H. Besselink
Ignace H. J. T. de Hingh
Albert J. ten Tije
Gijs A. Patijn
Bert A. Bonsing
Judith de Vos-Geelen
Joost M. Klaase
Sebastiaan Festen
Djamila Boerma
Joris I. Erdmann
I. Quintus. Molenaar
Erwin van der Harst
Marion B. van der Kolk
Coen R. N. Rasch
Geertjan van Tienhoven
Trials, 17
[39] Folfirinox versus gemcitabine/nab-paclitaxel for neoadjuvant treatment of resectable and borderline resectable pancreatic adenocarcinoma: A propensity matched analysis.
Dhir, Mashaal
Zenati, Mazen S.
Hamad, Ahmad
Singhi, Aatur D.
Bahary, Nathan
Hogg, Melissa Ellen
Zeh, Herbert
Zureikat, Amer H.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
[40] Neoadjuvant FOLFIRINOX and IMRT concurrent with FDR-gemcitabine in patients with borderline resectable pancreatic cancer (BRPC).
Tran, Nguyen H.
Sahai, Vaibhav
Griffith, Kent A.
Nathan, Hari
Kaza, Ravi
Cuneo, Kyle Clifford
Sonnenday, Christopher J.
Cho, Clifford
Lawrence, Theodore Steven
Zalupski, Mark
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)

← 1 2 3 4 5 →